copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Innovation in Cachexia - Actimed Actimed Therapeutics Announces New Programme to Investigate Potential Muscle Preservation Effects of S-pindolol Benzoate in Obese Patients Treated with GLP-1 Agonists
Actimed - About us Two of our founders, Professor Andrew Coats and Professor Stefan Anker, are world-leading physicians in cachexia research Actimed is led by a Management Team and Board with significant global experience in the development of new therapeutics across multiple indications
Actimed - Actimed Therapeutics Announces Professor David Ebsworth to . . . Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, announces that Professor David Ebsworth will assume the role of Executive Chairman of Actimed
S-oxprenolol (ACM-002) - Actimed Actimed Therapeutics Announces US FDA Grant of Orphan Drug Designation to S-oxprenolol (ACM-002) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) London, UK – 4th September 2024
Actimed - Actimed Therapeutics Expands Intellectual Property Portfolio Actimed is currently preparing for further clinical studies of its lead product ACM-001 1 (S-pindolol benzoate) which is an anti-catabolic and pro-anabolic transforming agent (ACTA) targeting multiple pathways that drive cancer cachexia
S-pindolol benzoate (ACM-001. 1) - Actimed In May 2025, Actimed initiated a new development programme investigating the potential benefits of using S-pindolol benzoate (ACM-001 1) during and post-GLP-1 receptor agonist (GLP-1RA) therapy in the management of obesity and related metabolic conditions
S-pindolol benzoate (ACM-001. 1) - Actimed In May 2025, Actimed initiated a new development programme investigating the potential benefits of using S-pindolol benzoate (ACM-001 1) during and post-GLP-1 receptor agonist (GLP-1RA) therapy in the management of obesity and related metabolic conditions
Actimed - Actimed Therapeutics Appoints Shaun Claydon as Chief . . . Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, today announces the appointment of Shaun Claydon as Chief Financial Officer
Press releases - Actimed Actimed Therapeutics Announces US FDA Grant of Orphan Drug Designation to S-oxprenolol (ACM-002) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)